Global drug giant boosts Boulder biotech's funding round to $150 million
The company's molecular research and drug-development platform taps what it calls nature's wisdom to drive the discovery of ...
The Pharma Letter1d
Sanofi investment latest validation of Enveda’s potential
Enveda, a Colorado-based biotech, has received a $20 million investment from French pharma major Sanofi. According to Enveda, ...
Enveda Gains Backing from Sanofi to Advance AI-Driven Drug Discovery to Clinical Trials Bringing Total Series C Financing to $150M
Sanofi invests in Enveda, reaffirming the industry’s confidence in its AI drug discovery platform and ability to deliver differentiated medicines.
Pharmabiz8h
Enveda gets support from Sanofi to advance AI-driven drug discovery to clinical trials
Enveda gets support from Sanofi to advance AI-driven drug discovery to clinical trials: Boulder, Colorado Friday, February 28, 2025, 16:00 Hrs [IST] Enveda, a leading biotechnolog ...
BizWest1d
Enveda adds millions to Series C haul
Boulder-based Enveda Biosciences, which uses machine learning to discover naturally occurring drug compounds, recently added ...
Le Lézard2d
Sway Medical, Inc. Announces FDA 510(k) Clearance of its Comprehensive Concussion Management System
Sway Medical, Inc., the company that created the Mobile Concussion Management category, is proud to announce that it has received FDA 510(k) clearance as a Computerized Cognitive Assessment Aid for ...
Le Lézard2d
Pykus Therapeutics Expands Patent Portfolio for PYK-2101, a First-in-class Retinal Sealant Delivery Technology
Pykus Therapeutics, Inc. ("Pykus" or the "Company"), a medical technology company dedicated to improving the lives of patients with blinding eye diseases, today announced it has secured a new patent ...
Yahoo Finance23d
Enveda Expands into Asthma with First-in-Class Lead Asset ENV-294 and Assembles World-Class Advisory Board
Enveda has since identified asthma as a high-impact follow-on indication for ENV-294 following promising preclinical and translational data in asthma models. This expansion underscores the company ...
FierceBiotech29d
Sanofi cuts programs tied to multibillion-dollar deals from pipeline
Sanofi has removed (PDF) a clutch of programs from its clinical pipeline, scratching out entries for its late-phase BTK inhibitor and phase 1 prospects linked to the multibillion-dollar takeovers ...
FiercePharma29d
Sanofi's RSV antibody Beyfortus, after smashing blockbuster sales threshold, still has room to grow in US: execs
While Sanofi’s immunology megablockbuster Dupixent predictably dominated the company’s sales charts in 2024, a new golden child could be emerging in the form of Beyfortus. During its first ...
Joplin Globe23d
Enveda Expands into Asthma with First-in-Class Lead Asset ENV-294 and Assembles World-Class Advisory Board
Enveda, a biotechnology company using AI to translate nature into new medicines, is proud to announce testing of its lead asset, ENV-294, in a second indication: asthma. This novel therapeutic ...
Business Insider8d
Sanofi treatment of autoimmune hemolytic anemia granted orphan status
The FDA granted orphan designation to Sanofi (SNY) US Services’ rilzabrutinib as a treatment of autoimmune hemolytic anemia, according to a post to the agency’s website. Published first on ...